Bandingkan Harga & Kinerja Merdeka Gold Resources Tbk. (EMAS) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Merdeka Gold Resources Tbk. dan Organon Pharma Indonesia Tbk.: Merdeka Gold Resources Tbk. diperdagangkan di Rp8.750 (kapitalisasi pasar 126,69 T, volume 24 jam 21,27 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Merdeka Gold Resources Tbk. jauh lebih besar — sekitar 1213,5× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| EMAS | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 126,69 T | 104,4 M |
Volume | 21,27 jt | — |
Lot | 212,69 rb | — |
Perputaran | 185,05 M | — |
Harga Rata-rata | 8.700,43 | — |
Nilai Transaksi | 185,05 M | — |
Harga Ekuilibrium Indikatif | 8.750 | — |
Volume Ekuilibrium Indikatif | 10,1 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Merdeka Gold Resources Tbk.
PT Merdeka Gold Resources Tbk (formerly PT Pani Bersama Jaya) (the Company), was established in Republic of Indonesia based on Deed of Establishment No. 87 dated 20 November 2015 made before Humberg Lie, S.H., S.E., M.Kn., Notary in North Jakarta. The ultimate parent entity of the Company is PT Merdeka Copper Gold Tbk (MCG). Meanwhile, MCG is jointly controlled by PT Provident Capital Indonesia and PT Saratoga Investama Sedaya Tbk, which are respectively controlled by Winato Kartono and Edwin Soeryadjaya.
Selengkapnya di halaman EMAS →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
